News Category
Creative Biolabs is promoting its tumor organoid and immune cell co-culture services, including CAR-T models, to provide more physiologically relevant...
Creative Biolabs has launched an integrated OMV and exosome-boosted CAR-T development platform to help researchers address the key barriers limiting C...
GeoVax's $1 million revolving loan from Bowery Consulting Group comes with a major governance shake-up, as five directors resign and three lender nomi...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business to execute a Phase 2 trial of Lucid...
VERAXA Biotech is implementing FDA-aligned New Approach Methodologies to cut animal use and speed up development of its antibody-based cancer therapie...
Lantern Pharma receives Taiwan regulatory and IRB approvals to open Part 2 of its Phase 2 HARMONIC trial of LP-300, potentially accelerating developme...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business to implement a Phase 2 trial of Luc...
VERAXA Biotech's adoption of FDA-aligned New Approach Methodologies could significantly reduce animal testing and accelerate the development of its ne...
XORTX Therapeutics is advancing XORLO, a proprietary oxypurinol formulation, toward an FDA new drug application, aiming to address the growing need fo...
New research reveals lymph node-like structures in the skull's bone marrow that could mobilize immune responses against brain diseases, opening doors ...
A blood-based method for identifying cancer-specific proteins could replace the need for surgical tumor biopsies, potentially accelerating the develop...
In vitro ADME studies are critical for early drug candidate assessment, improving success rates and reducing costs in pharmaceutical development.
GeoVax's next-generation MVA-X vaccine demonstrated durable single-dose protection against lethal Clade I mpox and other orthopoxviruses in preclinica...
Onco-Innovations is integrating manufacturing, preclinical and regulatory activities for its lead cancer candidate ONC010, aiming to advance it toward...
VERAXA Biotech's appointment of Raju Willener as CFO brings deep capital markets expertise to advance its BiTAC oncology pipeline, signaling a strateg...
Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) has engaged IBN to enhance its corporate communications strategy as its subsidiary MindWave Inn...
Regentis Biomaterials CEO Dr. Ehud Geller discussed the company's lead product GelrinC for knee cartilage repair, its U.S. pivotal trial and European ...
Silo Pharma's U.S. patent allowance for SPC-15 strengthens its intellectual property portfolio and supports the development of a novel intranasal trea...
Regentis Biomaterials is advancing GelrinC, a hydrogel implant designed to regenerate knee cartilage, with European approval and an FDA-authorized piv...
Med-X is advancing its Nature-Cide natural pest-control brand as it prepares for a Nasdaq listing, with recent OMRI certification opening opportunitie...
Telomir Pharmaceuticals' Telomir-Zn demonstrated growth inhibition in human and canine osteosarcoma cell lines, supporting further studies that could ...
Quantum BioPharma's FDA clearance of its IND for Lucid-MS allows the company to initiate a Phase 2 trial in multiple sclerosis, a critical step for a ...
GeoVax's agreement with CEPI to use its Centralised Laboratory Network for the Phase 3 trial of GEO-MVA aims to provide independent validation and div...
Tevard Biosciences and collaborators published preclinical research in Science Advances demonstrating that engineered suppressor tRNAs can restore ful...
Creative Biolabs has expanded its functionalized lipid-based delivery system capabilities to help researchers overcome stability, targeting, and contr...
Creative Biolabs has expanded its single-cell multi-omics and RNA sequencing services, offering high-resolution tools that overcome long-standing samp...
A comprehensive review reveals that the tumor microenvironment actively reprograms natural killer cells into distinct subsets with specialized functio...
GeoVax Labs is appealing a Nasdaq delisting determination while continuing to advance its GEO-MVA vaccine and Gedeptin oncology programs, highlighting...
Regentis Biomaterials reports progress in its Phase III GelrinC trial for knee cartilage repair and receives European approval for a manufacturing pro...
Quantum BioPharma's Lucid-MS, a first-in-class drug that protects and rebuilds myelin, has received FDA clearance for a Phase 2 trial that could trans...
TransCode Therapeutics names John Tattory as interim CFO following Tom Fitzgerald's retirement, bringing extensive financial leadership to guide the c...
VERAXA Biotech's appointment of Dr. Christoph Erkel as chief scientific officer strengthens its leadership as it advances its BiTAC® T-cell engager an...
Quantum BioPharma's FDA clearance for a phase 2 trial of Lucid-MS, a first-in-class myelin-repair therapy, could transform the multibillion-dollar mul...
Quantum BioPharma's Lucid-MS, a first-in-class PAD2 inhibitor, has received FDA clearance to begin a Phase 2 trial for multiple sclerosis, potentially...
Quantum BioPharma's FDA clearance for a phase 2 trial of Lucid-MS represents a historic first in multiple sclerosis treatment, potentially unlocking a...
Helus Pharma's CEO will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference, highlighting the company's advanced clinica...
Onco-Innovations' CMO detailed the company's novel PNKP-targeting drug candidate ONC010, which uses synthetic lethality and nanoparticle delivery to p...
Quantum BioPharma's Lucid-MS, a first-in-class non-covalent PAD2 inhibitor, has received FDA clearance to begin a Phase 2 trial in multiple sclerosis,...
American Fusion Inc. has moved its Texatron fusion program into active testing, achieving peak confinement pressures of approximately 100,000 atmosphe...
Kairos Pharma's CEO presentation at a major investment conference underscores the company's progress in developing ENV-105, an antibody aimed at rever...
Nutriband's CEO participation at the Nasdaq LaB summit underscores the importance of its AVERSA technology in addressing opioid abuse, potentially inf...
Silo Pharma's participation in the IPAC-RS 2026 Nasal Innovation Forum underscores its commitment to advancing SPC-15, a nose-to-brain therapy for PTS...
Quantum BioPharma's FDA clearance to advance Lucid-MS into Phase 2 trials marks a significant milestone for a novel myelin-repair approach to multiple...
Quantum BioPharma's multiple sclerosis drug candidate Lucid-MS has received FDA clearance to begin a Phase 2 trial, a rare milestone for a micro-cap b...
Helus Pharma's CEO participation in a major investment conference highlights the company's progress in developing novel serotonergic agonists for ment...
GeoVax applauds the new global mpox vaccine stockpile and highlights its GEO-MVA candidate's readiness to support a diversified supply.
Voyageur Pharmaceuticals has met the first milestone under its Bayer collaboration, receiving USD $1 million to advance a feasibility study for domest...
Greenland Mines is spinning off its biotech division in Q4 2026 to focus on rare earths, following the completion of its Sarfartoq acquisition and a p...
